Cosyntropin for the Treatment of Refractory Postdural Puncture Headache in Pediatric Patients : A Retrospective Review
OBJECTIVES: Postdural puncture headache is a challenging complication of diagnostic, therapeutic, and unintentional lumbar puncture. Literature evidence supports cosyntropin as a viable noninvasive therapy for adults who have failed conservative management, but pediatric data are limited. The purpose of this retrospective chart review was to describe the use of intravenous cosyntropin for refractory pediatric postdural puncture headache at a single free-standing tertiary care pediatric hospital.
METHODS: Patients who had received cosyntropin were identified. Charts were retrospectively reviewed for indication, dosing information, efficacy, and side effects. The response was defined as a 50% reduction in pain score, with a secondary efficacy measure of time to discharge after the first dose.
RESULTS: Over a 5-year period, 26 patients received 37 doses of cosyntropin. Dosing ranged from 5 to 15 mcg/kg (median, 10.4 mcg/kg). There was a significant reduction in pain scores after the first dose of cosyntropin (P=0.008). Eighty-one percent of patients (n=21) achieved either a 50% reduction in pain or were discharged within 24 hours after the first dose. The median time to 50% pain reduction in 13 patients who achieved it before or discharge was 5 hours (range, 1 to 30 h). The median time to discharge after the first dose was 20 hours (range, 2 to 72 h). Ten patients received >1 dose of cosyntropin. Three patients required an epidural blood patch. No adverse effects related to treatment were identified.
DISCUSSION: This study suggests that while further research is warranted, cosyntropin is a potential alternative to epidural blood patch for pediatric patients with postdural puncture headache who fail conservative management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
The Clinical journal of pain - 36(2020), 3 vom: 01. März, Seite 213-218 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zapapas, Michelle K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
16960-16-0 |
|---|
| Anmerkungen: |
Date Completed 23.07.2021 Date Revised 23.07.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/AJP.0000000000000784 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM303918888 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM303918888 | ||
| 003 | DE-627 | ||
| 005 | 20231225113847.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/AJP.0000000000000784 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1013.xml |
| 035 | |a (DE-627)NLM303918888 | ||
| 035 | |a (NLM)31789828 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zapapas, Michelle K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cosyntropin for the Treatment of Refractory Postdural Puncture Headache in Pediatric Patients |b A Retrospective Review |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.07.2021 | ||
| 500 | |a Date Revised 23.07.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Postdural puncture headache is a challenging complication of diagnostic, therapeutic, and unintentional lumbar puncture. Literature evidence supports cosyntropin as a viable noninvasive therapy for adults who have failed conservative management, but pediatric data are limited. The purpose of this retrospective chart review was to describe the use of intravenous cosyntropin for refractory pediatric postdural puncture headache at a single free-standing tertiary care pediatric hospital | ||
| 520 | |a METHODS: Patients who had received cosyntropin were identified. Charts were retrospectively reviewed for indication, dosing information, efficacy, and side effects. The response was defined as a 50% reduction in pain score, with a secondary efficacy measure of time to discharge after the first dose | ||
| 520 | |a RESULTS: Over a 5-year period, 26 patients received 37 doses of cosyntropin. Dosing ranged from 5 to 15 mcg/kg (median, 10.4 mcg/kg). There was a significant reduction in pain scores after the first dose of cosyntropin (P=0.008). Eighty-one percent of patients (n=21) achieved either a 50% reduction in pain or were discharged within 24 hours after the first dose. The median time to 50% pain reduction in 13 patients who achieved it before or discharge was 5 hours (range, 1 to 30 h). The median time to discharge after the first dose was 20 hours (range, 2 to 72 h). Ten patients received >1 dose of cosyntropin. Three patients required an epidural blood patch. No adverse effects related to treatment were identified | ||
| 520 | |a DISCUSSION: This study suggests that while further research is warranted, cosyntropin is a potential alternative to epidural blood patch for pediatric patients with postdural puncture headache who fail conservative management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Cosyntropin |2 NLM | |
| 650 | 7 | |a 16960-16-0 |2 NLM | |
| 700 | 1 | |a Gralla, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Suhong |e verfasserin |4 aut | |
| 700 | 1 | |a Eisdorfer, Seth |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Clinical journal of pain |d 1992 |g 36(2020), 3 vom: 01. März, Seite 213-218 |w (DE-627)NLM013185667 |x 1536-5409 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2020 |g number:3 |g day:01 |g month:03 |g pages:213-218 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/AJP.0000000000000784 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2020 |e 3 |b 01 |c 03 |h 213-218 | ||